Production of trimeric SARS‐CoV‐2 spike protein by CHO cells for serological COVID‐19 testing

Получение тримерного спайкового белка SARS-CoV-2 клетками CHO для серологического тестирования на COVID-19
Yusuf B. Johari, Stephen Jaffe, Joseph M. Scarrott, Abayomi O. Johnson, Théo Mozzanino, Thilo H. Pohle, Sheetal Maisuria, Amina Bhayat‐Cammack, Giulia Lambiase, Adam Brown, Kang Lan Tee, Philip J. Jackson, Tuck Seng Wong, Mark J. Dickman, Ravishankar Sargur, David C. James
2020-10-31

CHO cell productionELISA antibody assaySARS-CoV-2 spike proteinserological COVID-19 testingtrimeric glycoprotein
We describe scalable and cost-efficient production of full length, His-tagged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein trimer by Chinese hamster ovary (CHO) cells that can be used to detect SARS-CoV-2 antibodies in patient sera at high specificity and sensitivity. Transient production of spike in both human embryonic kidney (HEK) and CHO cells mediated by polyethyleneimine was increased significantly (up to 10.9-fold) by a reduction in culture temperature to 32°C to permit extended duration cultures. Based on these data GS-CHO pools stably producing spike trimer under the control of a strong synthetic promoter were cultured in hypothermic conditions with combinations of bioactive small molecules to increase yield of purified spike product 4.9-fold to 53 mg/L. Purification of recombinant spike by Ni-chelate affinity chromatography initially yielded a variety of co-eluting protein impurities identified as host cell derived by mass spectrometry, which were separated from spike trimer using a modified imidazole gradient elution. Purified CHO spike trimer antigen was used in enzyme-linked immunosorbent assay format to detect immunoglobulin G antibodies against SARS-CoV-2 in sera from patient cohorts previously tested for viral infection by polymerase chain reaction, including those who had displayed coronavirus disease 2019 (COVID-19) symptoms. The antibody assay, validated to ISO 15189 Medical Laboratories standards, exhibited a specificity of 100% and sensitivity of 92.3%. Our data show that CHO cells are a suitable host for the production of larger quantities of recombinant SARS-CoV-2 trimer which can be used as antigen for mass serological testing.
1
A modified imidazole-gradient purification separated host-cell protein impurities from recombinant spike trimers, as confirmed by mass spectrometry.
2
An ELISA using purified CHO-derived spike trimer achieved 100% specificity and 92.3% sensitivity for detecting SARS-CoV-2 IgG antibodies and was validated to ISO 15189 standards.
3
Hypothermic culture combined with bioactive small molecules increased purified spike-trimer yield 4.9-fold, reaching 53 mg/L in stable GS-CHO pools.
4
Reducing culture temperature to 32°C increased transient spike production in HEK and CHO cells by up to 10.9-fold.
5
Scalable CHO-cell production generated full-length, His-tagged trimeric SARS-CoV-2 spike protein suitable for serological testing.

Full-length His-tagged trimeric SARS-CoV-2 spike glycoprotein produced by CHO cells and used as a serological assay antigen

Scalable production, purification, and serological diagnostic performance of the recombinant spike trimer, including antibody-assay specificity and sensitivity

Publication Details
Publication Date
2020-10-31
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Yusuf B. Johari
Stephen Jaffe
Joseph M. Scarrott
Abayomi O. Johnson
Théo Mozzanino
Thilo H. Pohle
Sheetal Maisuria
Amina Bhayat‐Cammack
Giulia Lambiase
Adam Brown
Kang Lan Tee
Philip J. Jackson
Tuck Seng Wong
Mark J. Dickman
Ravishankar Sargur
David C. James
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%